Back HIV/AIDS HIV/AIDS Topics HIV Treatment

BMS Licenses Atazanavir to Medicines Patent Pool, Allowing Cheaper Generics

Bristol-Myers Squibb and the Medicines Patent Pool have reached a licensing agreement that will enable generic drug manufacturers to produce inexpensive versions of the HIV protease inhibitor atazanavir (Reyataz), as well as fixed-dose combinations containing the drug, for use in low-income countries, MPP recently announced. It is the first MPP agreement to cover a preferred second-line therapy.

alt

Read more:

IDSA Issues New Guidelines for Vaccination of Immune-compromised People

The Infectious Diseases Society of America (IDSA) this month released new recommendations for vaccinations for people with HIV and other immune-compromising conditions. The guidelines were published in the December 4, 2013, advance edition of Clinical Infectious Diseases.

alt

Read more:

HIV Re-emerges in Boston Bone Marrow Transplant Patients

Two bone marrow stem cell recipients who had undetectable HIV according to the most sensitive tests for months after an experimental antiretroviral therapy (ART) interruption have experienced viral rebound and had to restart treatment, frustrating hopes for a functional cure, according to a report at the 6th International Workshop on HIV Persistence during Therapy last week in Miami.

alt

Read more:

Conditioning with Cytoxan Increases Protected Cells in HIV Gene Therapy Trial

Administering cyclophosphamide (Cytoxan), a chemotherapy drug toxic to certain immune cells, prior to zinc-finger gene therapy appears to make room for increased proliferation of altered CD4 T-cells lacking the CCR5 co-receptor, researchers reported at the 6th International Workshop on HIV Persistence during Therapy last week in Miami.

alt

Read more:

HIV Integrase Inhibitor Elvitegravir Approved in European Union

The next-generation HIV integrase inhibitor elvitegravir has been approved by the European Commission, to be marketed under the brand name Vitekta, according to an announcement this week from developer Gilead Sciences. It is indicated for use in combination antiretriviral regimens containing a ritonavir-boosted protease inhibitor.

alt

Read more:

Antiretroviral Treatment Has Saved Nearly 3 Million Life-years in South Africa

Widespread use of effective antiretroviral therapy (ART) has led to "massive benefits" in hard-hit South Africa, saving an estimated 2.8 million life-years by 2012, and potentially up to 22 million years over the lifetime of treated individuals, according to a modeling study described in the December 3, 2013, advance edition of the Journal of Infectious Diseases.

alt

Read more:

The Lancet/Cell Conference Asks: What Will it Take to Achieve an AIDS-free World?

"What will it take to achieve and AIDS-free world?" was the question on everyone's mind at a small meeting of the same name held November 3-5 at the St. Francis Hotel in San Francisco. A Cell press release stated that the goal of the meeting was to "bridge the gap between researchers and clinicians in a joint effort to identify what needs to be done before an AIDS-free world can go from dream to reality."

alt

Read more: